Curated News
By: NewsRamp Editorial Staff
October 12, 2026
DuLac Farmaceutici Pursues U.S. Retail Partners After ECRM 2026
TLDR
- DuLac Farmaceutici expands U.S. retail presence after ECRM 2026, leveraging a 4.5-star Amazon rating to gain advantage in health and mass channels.
- DuLac Farmaceutici follows up with retail partners after ECRM 2026, leveraging its Italian manufacturing and botanical expertise to enter U.S. distribution channels.
- DuLac Farmaceutici brings Italian botanical expertise to U.S. retail, aiming to improve everyday health with high-quality dermo-cosmetic products.
- DuLac Farmaceutici, an Italian pharmaceutical company with 30 years of experience, is expanding its U.S. retail presence after ECRM 2026.
Impact - Why it Matters
This news matters because it signals the continued expansion of European pharmaceutical brands into the U.S. market, offering consumers more options for high-quality, botanically-based dermo-cosmetic products. DuLac’s move could lead to increased availability of its popular Arnica Gel and other Italian-formulated products in mainstream retail channels, giving shoppers easier access to trusted European pharmacy heritage. For retailers, partnering with DuLac means tapping into a growing demand for natural, effective skincare and wellness solutions, backed by strong consumer ratings. Ultimately, this expansion could raise the bar for product quality and innovation in the U.S. health and beauty sector.
Summary
DuLac Farmaceutici, an Italian pharmaceutical company with over 30 years of expertise in dermo-cosmetic products, is actively pursuing U.S. retail and distribution partnerships following its participation in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session, held September 14-17 in Palm Beach Gardens, Florida. The event allowed DuLac to present its Italian-developed portfolio to buyers across health, specialty, food, drug, and mass retail channels. The company is now following up on those conversations to explore product assortment and distribution opportunities, aiming to expand beyond its existing Amazon business.
DuLac’s portfolio includes its high-concentration Arnica Gel 98% range, topical leg-care products, and the Dinaven and Diosmin lines, all reflecting the company’s botanical formulation capabilities and pharmaceutical-grade manufacturing. The company already has a U.S. e-commerce presence through its Amazon storefront and OneLavi. Notably, its Arnica Gel 98% listing on Amazon.com holds an average customer rating of 4.5 out of 5 stars, providing prospective partners with a reference point for consumer feedback. “Our priority following ECRM is to work with prospective partners to identify the DuLac products that best fit their customers and channels,” said Gabriele Bollani, Founder and CEO. “We want to build lasting relationships by combining our Italian formulation and manufacturing expertise with a clear understanding of each partner’s commercial needs.”
During the ECRM meetings, DuLac highlighted its proprietary Arnica Montana Arricchita™ project and advanced extraction technologies. The company’s long-term objective is to establish DuLac as a nationally recognized U.S. brand across multiple channels, leveraging its European pharmacy heritage and Italian manufacturing. For more information, visit DuLac Farmaceutici USA, the company’s Amazon Storefront, or OneLavi.
Source Statement
This curated news summary relied on content distributed by Newsworthy.ai. Read the original source here, DuLac Farmaceutici Pursues U.S. Retail Partners After ECRM 2026
